Director of PK Technology/Operations
Genentech
South San Francisco, California
Douglas Leipold, MS is a Director of PK Technology/Operations and a Staff Scientist I Researcher in Preclinical & Translational Pharmacokinetics (PTPK) Department within Development Sciences at Genentech. Doug has been at Genentech for nearly 24 years and has extensive drug development experience most notably with Antibody Drug Conjugates (ADCs) as w ell as immunoncology (IO) efforts, includingT-cell Dependent Bi-specifics (TDBs). My work with ADCs includes extensive work and expertise primarily in the early development and PK/PD modeling/characterization of ADCs through FIH/Ph1 development. My experience includes early generation ADCs (e.g. Kadcyla), but have pivoted my work along with the industry to newer payload classes, linker technology and conjugation strategies.
Disclosure information not submitted.
Tuesday, October 22, 2024
2:30 PM – 3:00 PM MT